Figure 12

![Figure 12: Comparative timeline of clinical trials assessing mitochondria-targeting nutraceuticals in patients with mild cognitive impairment, charting enrollment, intervention periods, and primary endpoint assessments.]()

> Source: Imane Lejri et al. "Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Rel." *Oxidative medicine and cellular longevity*, 2019. PMID: [31214285](https://pubmed.ncbi.nlm.nih.gov/31214285/)

<figure>
  <img src="" alt="Comparative timeline of clinical trials assessing mitochondria-targeting nutraceuticals in patients with mild cognitive impairment, charting enrollment, intervention periods, and primary endpoint assessments." />
  <figcaption>Figure 12. Comparative timeline of clinical trials assessing mitochondria-targeting nutraceuticals in patients with mild cognitive impairment, charting enrollment, intervention periods, and primary endpoint assessments.<br>  Source: Imane Lejri et al. "Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Rel." <em>Oxidative medicine and cellular longevity</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31214285/">31214285</a></figcaption>
</figure>